ReviewCurrent opinion in HIV and AIDS2015
Antibody engineering for increased potency, breadth and half-life.
Review in Current opinion in HIV and AIDS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.Nature medicine · 2021Trial
- Engineering HIV antibodies with enhanced breadth and potency of neutralization through multistate affinity maturation.bioRxiv : the preprint server for biology · 2025Article
- Challenges and Potential of Antibody-Drug Conjugates as Prospective Tuberculosis Therapeutics.Microorganisms · 2025Review
- Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.Clinical microbiology reviews · 2024Review
- A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.Journal of virology · 2024Article
- Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody.Science translational medicine · 2023Article
- Common framework mutations impact antibody interfacial dynamics and flexibility.Frontiers in immunology · 2023Article
- Current Advances in Zika Vaccine Development.Vaccines · 2022Review
- Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.International journal of molecular sciences · 2022Review
- A naturally arising broad and potent CD4-binding site antibody with low somatic mutation.Science advances · 2022Article
- Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile.iScience · 2021Article
- The reduced form of the antibody CH2 domain.Protein science : a publication of the Protein Society · 2021Article
- Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.Science (New York, N.Y.) · 2021Article
- COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research.Current opinion in HIV and AIDS · 2021Review
- Determination of variable region sequences from hybridoma immunoglobulins that target Mycobacterium tuberculosis virulence factors.PloS one · 2021Article
- Advances in Antibody Preparation Techniques for Immunoassays of Total Aflatoxin in Food.Molecules (Basel, Switzerland) · 2020Review
- A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.ACS chemical biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewThis review highlights recent developments in HIV-1 antibody engineering and discusses the effects of increased polyreactivity on serum half-lives of engineered antibodies. RECENT
findingsRecent studies have uncovered a wealth of information about the relationship between the sequences and efficacies of anti-HIV-1 antibodies through a combination of bioinformatics, structural characterization and in vivo studies. This knowledge has stimulated efforts to enhance antibody breadth and potency for therapeutic use. Although some engineered antibodies have shown increased polyreactivity and short half-lives, promising efforts are circumventing these problems. SUMMARY: Antibodies are desirable as therapeutics due to their ability to recognize targets with both specificity and high affinity. Furthermore, the ability of antibodies to stimulate Fc-mediated effector functions can increase their utility. Thus, mAbs have become central to strategies for the treatment of various diseases. Using both targeted and library-based approaches, antibodies can be engineered to improve their therapeutic properties. This article will discuss recent antibody engineering efforts to improve the breadth and potency of anti-HIV-1 antibodies. The polyreactivity of engineered HIV-1 bNAbs and the effect on serum half-life will be explored along with strategies to overcome problems introduced by engineering antibodies. Finally, advances in creating bispecific anti-HIV-1 reagents are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.